CSL possible pull back to low $200's, page-71

".... and yes, the margin remains the same, therefore it follows that such huge increase in product flows through to proprtionate positive increase in profit... "

Which suggests that, irrespective of what happens to the cost structure of the company, it simply gets to exercise an inalienable right to ratchet its price list upwards, and thereby generate even greater Returns on Capital (given those higher profits arise off no larger an asset base), than the Returns on Capital which are already many multiples higher than the company's Cost of Capital.

So CSL's financial returns are to become even more excellent than they already are, at the expense of higher treatment costs for the people who depend on CSL's products.

Is that really what discerning shareholders desire?

From an ethical standpoint, when doing business specifically in the health care sector, acting to maximise profits - which are already super-normal - feels decidedly at odds with socially responsible corporate behaviour and the notion of sustainable business practices that balance doing well for shareholders as well as doing good for society.

.